Successful use of recombinant factor VIIa (NovoSeven) in children with compartment syndrome: two case reports.
Compartment syndrome (CS) is an uncommon bleeding manifestation in patients with liver failure and end-stage renal disease (ESRD). Although prompt intervention is paramount in preventing the tissue necrosis and the permanent functional deficits that may be associated with untreated CS, the indications for initiating therapies for children with CS are not standardized. In this report, we present 2 children, one with ESRD and the other with liver failure, who have CS related to life-threatening bleeding complications and were treated with recombinant factor VIIa (rFVIIa). In conclusion, treatment decisions for patients with CS should be made on a case-by-case basis. The use of rFVIIa is an effective and safe treatment in children with liver failure and ESRD. Surgical treatment should be preferred in patients with CS. However, in patients who have a coagulation defect, the first priority is to correct the clotting deficiency. The use of rFVIIa is a treatment option in children with CS due to a coagulation defect.
Alioglu
Bulent
B
Department of Pediatric Hematology, Baskent University Faculty of Medicine, Ankara, Turkey. alioglub@gmail.com
Avci
Zekai
Z
Baskin
Esra
E
Ozcay
Figen
F
Tuncay
Ismail Cengiz
IC
Ozbek
Namik
N
D000005:Abdomen; D000293:Adolescent; D003161:Compartment Syndromes / Q000188:drug therapy* / Q000209:etiology; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000150:complications; D017093:Liver Failure / Q000150:complications; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa